REFERENCES
1. Špinar J, Špinarová L, Vítovec J. Pathophysiology, causes and epidemiology of chronic heart failure. Vnitr Lek. 2018;64:834-8.
2. Bozkurt B, Coats AJ, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23:352-80.
3. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145:18.
5. Hummel A, Empen K, Dörr M, Felix SB. De novo acute heart failure and acutely decompensated chronic heart failure. Dtsch Arztebl Int. 2015;112:298-310.
6. Martens P, Dupont M, Verbrugge FH, et al. Urinary sodium profiling in chronic heart failure to detect development of acute decompensated heart failure. JACC Heart Fail. 2019;7:404-14.
7. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843-54.
8. Pasquinelli AE, Reinhart BJ, Slack F, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature. 2000;408:86-9.
9. Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000;403:901-6.
10. Lewis BP, Shih I, Jones-rhoades MW, Bartel DP, Burge CB. Prediction of mammalian MicroRNA targets. Cell. 2003;115:787-98.
11. Ren Z, Liu Y, Cai A, et al. Cannabidiol represses miR-143 to promote cardiomyocyte proliferation and heart regeneration after myocardial infarction. Eur J Pharmacol. 2024;963:176245.
12. Yaping X, Guotian Y, Dandan J, Jintao D, Xinyi L, Zhikun G. Fibroblast-derived exosomal miRNA-133 promotes cardiomyocyte-like differentiation. Acta Histochem. 2022;124:151931.
13. Lee T, Shen W, Chen Y, et al. Mir221- and Mir222-enriched adsc-exosomes mitigate PM exposure-exacerbated cardiac ischemia-reperfusion injury through the modulation of the BNIP3-MAP1LC3B-BBC3/PUMA pathway. Autophagy. 2024;21:374-93.
14. Schütte JP, Manke M, Hemmen K, et al. Platelet-derived MicroRNAs regulate cardiac remodeling after myocardial ischemia. Circ Res. 2023;132:e96-113.
15. Senesi G, Lodrini AM, Mohammed S, et al. miR-24-3p secreted as extracellular vesicle cargo by cardiomyocytes inhibits fibrosis in human cardiac microtissues. Cardiovasc Res. 2025;121:143-56.
16. Kornieieva D, Kalocayova B, Slezak J, Kura B. Exploring the potential of molecular hydrogen in different heart failure models: a review. Int J Mol Sci. 2025;26:11574.
17. Qian L, Zhao Q, Yu P, et al. Diagnostic potential of a circulating miRNA model associated with therapeutic effect in heart failure. J Transl Med. 2022;20:267.
18. Zhang Z, Zou Z, Zhang H, Zhang D. Regulatory network analysis based on integrated miRNA-TF reveals key genes in heart failure. Sci Rep. 2024;14:13896.
19. Gomes CPDC, Schroen B, Kuster GM, et al. Regulatory RNAs in heart failure. Circulation. 2020;141:313-28.
20. Paterek A, Załęska-Kocięcka M, Surzykiewicz M, Wojdyńska Z, Leszek P, Mączewski M. Non-coding RNA therapeutics in the treatment of heart failure. Eur Heart J Cardiovasc Pharmacother. 2024;10:353-60.
21. Li W, Liu M, Zhao C, et al. MiR-1/133 attenuates cardiomyocyte apoptosis and electrical remodeling in mice with viral myocarditis. Cardiol J. 2020;27:285-94.
23. Shirakabe A, Ikeda Y, Uchikado Y, et al. Prognostic impact of mitochondrial dynamics-related miRNA levels during the treatment of acute heart failure in the hospital. Sci Rep. 2025;15:39938.
24. Larocca TJ, Seeger T, Prado M, et al. Pharmacological silencing of MicroRNA-152 prevents pressure overload-induced heart failure. Circ Heart Fail. 2020;13:e006298.
25. Shirakabe A, Ikeda Y, Uchikado Y, et al. Prognostic impact of excessive mitochondrial fission in patients with heart failure and evaluation of mitochondrial dynamics-related miRNAs in heart failure. Hypertens Res. 2025;48:2950-60.
26. Mohamed DI, Ezzat SF, Elayat WM, et al. Hepatoprotective role of carvedilol against ischemic hepatitis associated with acute heart failure via targeting miRNA-17 and mitochondrial dynamics-related proteins: an in vivo and in silico study. Pharmaceuticals. 2022;15:832.
27. Micu MA, Cozac DA, Scridon A. miRNA-orchestrated fibroinflammatory responses in heart failure with preserved ejection fraction: translational opportunities for precision medicine. Diagnostics. 2025;15:2286.
28. Wypijewska Del Nogal A, Sundar Rajan V, Westerlund F, Wilhelmsson LM. Complex conformational dynamics of the heart failure-associated Pre-miRNA-377 hairpin revealed by single-molecule optical tweezers. Int J Mol Sci. 2021;22:9008.
29. He Y, Dai MS, Tao LY, Gu X, Wang H, Liu P. Pericarpium trichosanthis inhibits TGF‐β1‐Smad3 pathway‐induced cardiac fibrosis in heart failure rats via upregulation of microRNA‐29b. J Gene Med. 2025;27:e70003.
30. Tao Y, Gao C, Qian D, Cao D, Han L, Yang L. Regulatory mechanism of fibrosis-related genes in patients with heart failure. Front Genet. 2022;13:1032572.
31. Gisa V, Islam MR, Lbik D, et al. Role of compensatory miRNA networks in cognitive recovery from heart failure. ncRNA. 2025;11:45.
32. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005;6:376-85.
33. Kim H, Lee Y, Kim VN. The biogenesis and regulation of animal microRNAs. Nat Rev Mol Cell Biol. 2024;26:276-96.
35. Seida M, Ogami K, Yoshino S, Suzuki HI. Fine regulation of MicroRNAs in gene regulatory networks and pathophysiology. Int J Mol Sci. 2025;26:2861.
36. Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 2011;12:99-110.
37. Bologna NG, Voinnet O. The diversity, biogenesis, and activities of endogenous silencing small RNAs in Arabidopsis. Annu Rev Plant Biol. 2014;65:473-503.
38. Schirle NT, Sheu-Gruttadauria J, Macrae IJ. Structural basis for microRNA targeting. Science. 2014;346:608-13.
39. Jonas S, Izaurralde E. Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet. 2015;16:421-33.
40. Luisotti L, Germelli L, Piccarducci R, Giacomelli C, Marchetti L, Martini C. Extracellular vesicles as vehicles for small non-coding RNA therapeutics: standardization challenges for clinical translation. Extracell Vesicles Circ Nucleic Acids. 2025;6:398-427.
41. Akbar N, Azzimato V, Choudhury RP, Aouadi M. Extracellular vesicles in metabolic disease. Diabetologia. 2019;62:2179-87.
42. Huang W, Zhang Q, Qi H, et al. Deletion of neuropeptide Y attenuates cardiac dysfunction and apoptosis during acute myocardial infarction. Front Pharmacol. 2019;10:1268.
43. Sun T, Dong C, Xiong S. Cardiomyocyte‐derived HMGB1 takes a protective role in CVB3‐induced viral myocarditis via inhibiting cardiac apoptosis. Immunol Cell Biol. 2023;101:735-45.
44. Hao H, Yuan T, Li Z, et al. Curcumin analogue C66 ameliorates mouse cardiac dysfunction and structural disorders after acute myocardial infarction via suppressing JNK activation. Eur J Pharmacol. 2023;946:175629.
45. Mentkowski KI, Tarvirdizadeh T, Manzanero CA, Eagler LA, Lang JK. Surface engineering enhances the therapeutic potential of systemically delivered extracellular vesicles following acute myocardial infarction. FASEB J. 2024;38:e70070.
46. Lu C, Chen D, Dong K, et al. Inhibition of miR-143-3p alleviates myocardial ischemia reperfusion injury via limiting mitochondria-mediated apoptosis. Biol Chem. 2023;404:619-31.
47. Liao B, Dong S, Xu Z, Gao F, Zhang S, Liang R. MiR-19b-3p regulated by BC002059/ABHD10 axis promotes cell apoptosis in myocardial infarction. Biol Direct. 2022;17:20.
48. Zhang Q, Yu N, Yu BT. MicroRNA-298 regulates apoptosis of cardiomyocytes after myocardial infarction. Eur Rev Med Pharmacol Sci. 2018;22:532-9.
49. Wang Z, Wei TYW, Chen JMM, et al. MicroRNA‐100‐5p exacerbates myocardial ischemia-reperfusion injury through downregulation of PRMT5. FASEB J. 2025;39:e70690.
50. Xu C, Hu Y, Hou L, et al. β-Blocker carvedilol protects cardiomyocytes against oxidative stress-induced apoptosis by up-regulating miR-133 expression. J Mol Cell Cardiol. 2014;75:111-21.
51. Zong L, Wang W. CircANXA2 promotes myocardial apoptosis in myocardial ischemia-reperfusion injury via inhibiting miRNA‐133 expression. BioMed Res Int. 2020;2020:8590861.
52. Zhang J, Luo CJ, Xiong XQ, et al. MiR-21-5p-expressing bone marrow mesenchymal stem cells alleviate myocardial ischemia/reperfusion injury by regulating the circRNA_0031672/miR-21-5p/programmed cell death protein 4 pathway. J Geriatr Cardiol. 2021;18:1029-43.
53. Xiao J, Pan Y, Li XH, et al. Cardiac progenitor cell-derived exosomes prevent cardiomyocytes apoptosis through exosomal miR-21 by targeting PDCD4. Cell Death Dis. 2016;7:e2277.
54. Olson JM, Yan Y, Bai X, et al. Up-regulation of MicroRNA-21 mediates isoflurane-induced protection of cardiomyocytes. Anesthesiology. 2015;122:795-805.
55. Tang M, Pan H, Zheng Z, et al. Prostaglandin E1 protects cardiomyocytes against hypoxia-reperfusion induced injury via the miR-21-5p/FASLG axis. Biosci Rep. 2019;39:BSR20190597.
56. Wang Q, Xie Z. GAS5 silencing attenuates hypoxia‐induced cardiomyocytes injury by targeting miR‐21/PTEN. Immun Inflamm Dis. 2023;11:e945.
57. Liu Z, Wang H, Hou G, Cao H, Zhao Y, Yang B. Notoginsenoside R1 protects oxygen and glucose deprivation‐induced injury by upregulation of miR‐21 in cardiomyocytes. J Cell Biochem. 2018;120:9181-92.
58. Lv X, Lu P, Hu Y, Xu T. miR-346 inhibited apoptosis against myocardial ischemia-reperfusion injury via targeting bax in rats. Drug Des Devel Ther. 2020;14:895-905.
59. Jia Z, Wang J, Shi Q, et al. SOX6 and PDCD4 enhance cardiomyocyte apoptosis through LPS-induced miR-499 inhibition. Apoptosis. 2015;21:174-83.
60. Yang G, Tang X, Tan L, Nong D, Yang P, Ning H. Upregulation of miR-144-3p protects myocardial function from ischemia-reperfusion injury through inhibition of TMEM16A Ca2+-activated chloride channel. Hum Cell. 2021;34:360-71.
61. Zhao Z, Qu F, Liu R, Xia Y. Differential expression of miR‐142‐3p protects cardiomyocytes from myocardial ischemia‐reperfusion via TLR4/NFkB axis. J Cell Biochem. 2019;121:3679-90.
62. Zhu H, Wang X, Sun Y, et al. MicroRNA-486-5p targeting PTEN protects against coronary microembolization-induced cardiomyocyte apoptosis in rats by activating the PI3K/AKT pathway. Eur J Pharmacol. 2019;855:244-51.
63. Wang C, Zhang C, Liu L, et al. Macrophage-derived mir-155-containing exosomes suppress fibroblast proliferation and promote fibroblast inflammation during cardiac injury. Mol Ther. 2017;25:192-204.
64. Yang L, Dai Q, Bao X, Li W, Liu J. MiR-4763-3p accelerates lipopolysaccharide-induced cardiomyocyte apoptosis and inflammatory response by targeting IL10RA. Cytotechnology. 2023;76:179-90.
65. Xu M, Li X, Song L, Tao C, Fang J, Tao L. miR-484 targeting of Yap1-induced LPS-inhibited proliferation, and promoted apoptosis and inflammation in cardiomyocyte. Biosci Biotechnol Biochem. 2021;85:378-85.
66. Guo X, Ji Q, Wu M, Ma W. Naringin attenuates acute myocardial ischemia-reperfusion injury via miR- 126/GSK-3β/β-catenin signaling pathway. Acta Cir Bras. 2022;37:e370102.
67. Corsten MF, Heggermont W, Papageorgiou A, et al. The microRNA-221/-222 cluster balances the antiviral and inflammatory response in viral myocarditis. Eur Heart J. 2015;36:2909-19.
68. Ma C, Yang Z, Wang J, et al. Interleukin-1β-stimulated macrophage-derived exosomes improve myocardial injury in sepsis via regulation of mitochondrial homeostasis: experimental research. Int J Surg. 2025;111:283-301.
69. Diniz GP, Lino CA, Moreno CR, Senger N, Barreto‐Chaves MLM. MicroRNA‐1 overexpression blunts cardiomyocyte hypertrophy elicited by thyroid hormone. J Cell Physiol. 2017;232:3360-8.
70. Li Q, Song X, Zou J, et al. Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy. J Cell Sci. 2010;123:2444-52.
71. Diniz GP, Lino CA, Guedes EC, Nascimento Moreira LD, Barreto-Chaves MLM. Cardiac microRNA-133 is down-regulated in thyroid hormone-mediated cardiac hypertrophy partially via Type 1 Angiotensin II receptor. Basic Res Cardiol. 2015;110:49.
72. Liu X, Li H, Hastings MH, et al. miR-222 inhibits pathological cardiac hypertrophy and heart failure. Cardiovasc Res. 2024;120:262-72.
73. Zhao L, Qian X, Ren Z, Wang A. miR‐31‐5p suppresses myocardial hypertrophy by targeting Nfatc2ip. J Cell Mol Med. 2024;28:e18413.
74. Li J, Sha Z, Zhu X, et al. Targeting miR-30d reverses pathological cardiac hypertrophy. eBioMedicine. 2022;81:104108.
75. Huang X, Li J, Li X, et al. miR-208a in cardiac hypertrophy and remodeling. Front Cardiovasc Med. 2021;8:773314.
76. Heymans S, Corsten MF, Verhesen W, et al. Macrophage MicroRNA-155 promotes cardiac hypertrophy and failure. Circulation. 2013;128:1420-32.
77. Zhang Y, Ding Y, Li M, et al. MicroRNA-34c-5p provokes isoprenaline-induced cardiac hypertrophy by modulating autophagy via targeting ATG4B. Acta Pharm Sin B. 2022;12:2374-90.
78. Yu S, Wang M, Xie Y, Wang B, Xu Y. MiR-495-3p promotes cardiac hypertrophy by targeting Pum2. Cell Mol Biol. 2024;70:116-20.
79. Long M, Cheng M. Small extracellular vesicles associated miRNA in myocardial fibrosis. Biochem Biophys Res Commun. 2024;727:150336.
80. Liu B, Wei Y, He J, et al. Human umbilical cord-derived mesenchymal stromal cells improve myocardial fibrosis and restore miRNA-133a expression in diabetic cardiomyopathy. Stem Cell Res Ther. 2024;15:120.
81. Zhang SL, Fan FL, Wei F, Wang J, Zhang YS. Effect of microRNA-133b on myocardial fibrosis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2019;41:589-94.
82. Guo F, Tang C, Huang B, et al. LncRNA H19 drives proliferation of cardiac fibroblasts and collagen production via suppression of the miR-29a-3p/miR-29b-3p-VEGFA/TGF-β axis. Mol Cells. 2022;45:122-33.
83. Yuan J, Yang H, Liu C, et al. Microneedle patch loaded with exosomes containing MicroRNA‐29b prevents cardiac fibrosis after myocardial infarction. Adv Healthc Mater. 2023;12:2202959.
84. Wang Y, Yu J, Ou C, et al. miRNA-146a-5p inhibits hypoxia-induced myocardial fibrosis through EndMT. Cardiovasc Toxicol. 2024;24:133-45.
85. Huang D, Wen Q, Su Y, Li X. miR-17-5p inhibits BNIP3-mediated mitochondrial autophagy to attenuate pathological cardiac fibrosis. Balkan Med J. 2025;42:516-25.
86. Zhao H, Yang H, Geng C, et al. Elevated IgE promotes cardiac fibrosis by suppressing miR-486a-5p. Theranostics. 2021;11:7600-15.
87. Xia YW, Wang SB. Microvesicles containing microRNA-21 induce myocardial fibrosis via AKT pathway. Eur Rev Med Pharmacol Sci. 2018;22:4634-41.
88. Yuan J, Chen H, Ge D, et al. Mir-21 promotes cardiac fibrosis after myocardial infarction via targeting Smad7. Cell Physiol Biochem. 2017;42:2207-19.
89. Yang J, Yu X, Xue F, et al. Exosomes derived from cardiomyocytes promote cardiac fibrosis via myocyte-fibroblast cross-talk. Am J Transl Res. 2018;10:4350-66.
90. Cao F, Li Z, Ding W, Qv C, Zhao H. Exosomal miR-15a-5p from cardiomyocytes promotes myocardial fibrosis. Mol Cell Biochem. 2024;480:1701-13.
91. Wu H, Zhuang Y, Yue Y, et al. SPOP is a key trigger of pathological cardiac hypertrophy and heart failure. Circ Res. 2025;137:e177-96.
92. Jebran AF, Seidler T, Tiburcy M, et al. Engineered heart muscle allografts for heart repair in primates and humans. Nature. 2025;639:503-11.
93. Chen X, Yu X, Zhong S, et al. ALDH2/eIF3E interaction modulates protein translation critical for cardiomyocyte ferroptosis in acute myocardial ischemia injury. Circulation. 2026;153:164-84.
94. Ciccarelli M, Pires IF, Bauersachs J, et al. Acute heart failure: mechanisms and pre-clinical models—a scientific statement of the ESC working group on myocardial function. Cardiovasc Res. 2023;119:2390-404.
95. Li Q, Yao Y, Shi S, et al. Inhibition of miR‐21 alleviated cardiac perivascular fibrosis via repressing EndMT in T1DM. J Cell Mol Med. 2019;24:910-20.
96. Zhang Y, Yuan B, Xu Y, et al. MiR-208b/miR-21 promotes the progression of cardiac fibrosis through the activation of the TGF-β1/Smad-3 signaling pathway: an in vitro and in vivo study. Front Cardiovasc Med. 2022;9:924629.
97. Wang X, Zhang T, Zhai J, et al. MiR-21 attenuates FAS-mediated cardiomyocyte apoptosis by regulating HIPK3 expression. Biosci Rep. 2023;43:BSR20230014.
98. Holland A, Enrick M, Diaz A, Yin L. Is miR-21 a therapeutic target in cardiovascular disease? Int J Drug Discov Pharm. 2023;2:26-36.
99. Gozdowska R, Makowska A, Gąsecka A, Chabior A, Marchel M. Circulating microRNA in heart failure—practical guidebook to clinical application. Cardiol Rev. 2020;30:16-23.
100. Fathy WM, Montaser BA, Ibrahim WA, Salah DM, Aboelkhair NT. The role of microRNA-19b, microRNA-21, and microRNA-208a in diagnosis of heart failure. BMC Cardiovasc Disord. 2025;25:864.
101. Wong LL, Zou R, Zhou L, et al. Combining circulating MicroRNA and NT-proBNP to detect and categorize heart failure subtypes. J Am Coll Cardiol. 2019;73:1300-13.
102. Gallo A, Agnese V, Sciacca S, et al. MicroRNA-30d and -483-3p for Bi-ventricular remodelling and miR-126-3p for pulmonary hypertension in advanced heart failure. ESC Heart Fail. 2024;11:155-66.
103. Tong L, Wang Q, Zhang Y, et al. Myocardial delivery of miR30d with peptide-functionalized milk-derived extracellular vesicles for targeted treatment of hypertrophic heart failure. Biomaterials. 2025;316:122976.
104. Foinquinos A, Batkai S, Genschel C, et al. Preclinical development of a miR-132 inhibitor for heart failure treatment. Nat Commun. 2020;11:633.
105. Täubel J, Hauke W, Rump S, et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. Eur Heart J. 2021;42:178-88.
106. Zhou H, Tang W, Yang J, Peng J, Guo J, Fan C. MicroRNA-related strategies to improve cardiac function in heart failure. Front Cardiovasc Med. 2021;8:773083.
107. Forterre A, Komuro H, Aminova S, Harada M. A Comprehensive review of cancer MicroRNA therapeutic delivery strategies. Cancers. 2020;12:1852.
108. Wu Q, Yao X, Duan X, Chen X, Zhang J. Nanomedicine reimagined: translational strategies for precision tumor theranostics. Adv Mater. 2025;38:e10293.
109. Li X, Chen Y, Cao X, Feng W, Chen Y, Zhang J. Inflammatory macrophage-targeted atherosclerosis treatment by miRNA-delivered, MRI-visible, and anti-inflammatory nanomedicine. ACS Nano. 2025;19:20472-90.
110. Wang Z, Chen J, Wang J, et al. MSCs biomimetic ultrasonic phase change nanoparticles promotes cardiac functional recovery after acute myocardial infarction. Biomaterials. 2025;313:122775.
111. Nazari-shafti TZ, Exarchos V, Biefer HRC, et al. MicroRNA mediated cardioprotection - is there a path to clinical translation? Front Bioeng Biotechnol. 2020;8:149.
112. Gao L, Qiu F, Cao H, et al. Therapeutic delivery of microRNA-125a-5p oligonucleotides improves recovery from myocardial ischemia/reperfusion injury in mice and swine. Theranostics. 2023;13:685-703.
113. Chen Y, Liu S, Liang Y, et al. Single dose of intravenous miR199a-5p delivery targeting ischemic heart for long-term repair of myocardial infarction. Nat Commun. 2024;15:5565.
114. Baek ST, Kerjan G, Bielas SL, et al. Off-target effect of doublecortin family shRNA on neuronal migration associated with endogenous MicroRNA dysregulation. Neuron. 2014;82:1255-62.
115. Asensio Lopez MDC, Ruiz Ballester M, Bastida Nicolas FJ, et al. miR-106b-5p as a central regulator of cancer progression and chemotherapy-induced cardiotoxicity: from molecular mechanisms to clinical translation. Int J Mol Sci. 2025;26:10002.
116. Chen X, Chen H, Zhu L, et al. Nanoparticle-patch system for localized, effective, and sustained miRNA Administration into infarcted myocardium to alleviate myocardial ischemia-reperfusion injury. ACS Nano. 2024;18:19470-88.
117. Wang Y, Meng D, Shi X, et al. Injectable hydrogel with miR-222-engineered extracellular vesicles ameliorates myocardial ischemic reperfusion injury via mechanotransduction. Cell Rep Med. 2025;6:101987.
118. Hong DS, Kang Y, Borad M, et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020;122:1630-7.
119. Li W, Wang Y, Liu R, et al. MicroRNA-34a: potent tumor suppressor, cancer stem cell inhibitor, and potential anticancer therapeutic. Front Cell Dev Biol. 2021;9:640587.
120. Lv P, Zhou M, He J, et al. Circulating miR-208b and miR-34a are associated with left ventricular remodeling after acute myocardial infarction. Int J Mol Sci. 2014;15:5774-88.
